Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy
About This Grant
Project Summary/Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a very poor overall prognosis and limited treatment options. The absence of elevated expression of the three common receptors, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) that are validated targets of therapeutic drugs, poses significant challenges in treating TNBC. Better therapeutic options for efficient TNBC control and improved survival are urgently needed. In this investigation, we propose to develop antibody chelator conjugates (ACCs) for targeted radionuclide therapy of TNBC. The novel ACCs contain a monoclonal antibody with high affinity for a validated therapeutic target in TNBC and a chelating agent labeled with â..emitting therapeutic radionuclide (177Lu or 90Y). The efficacy of targeted radionuclide therapy against cancer has been demonstrated in numerous clinical trials with radiopharmaceuticals including 177Lu-based Lutathera®, 177Lu-based Pluvicto®, and 90Y-based Zevalin®. Chelation chemistry is an essential component in creating clinically viable radiotherapeutics with high therapeutic efficacy and safety profiles. The PI has invented highly effective chelators for 177Lu and 90Y in targeted radionuclide therapy. In this investigation, we aim to utilize superior chelation chemistry to create 177Lu- or 90Y-based ACCs for antibody-targeted therapy of TNBC. Promising ACCs will be identified and evaluated for radiolabeling with 177Lu or 90Y, and the corresponding 177Lu-ACCs and 90Y-ACCs will be evaluated for in vitro stability and radioimmunoassay. The top 177Lu-ACCs and 90Y-ACCs will be further evaluated for in vivo biodistribution, metabolism, radiation dosimetry, therapy, and toxicity using TNBC tumorbearing mice. The proposed in vivo studies are essential because data relevant to clinical procedures cannot be obtained using computational, invertebrate, or in vitro methods. This investigation is proposed to generate potent and safe 177Lu-ACCs and 90Y-ACCs as novel radiopharmaceuticals for TNBC Therapy.
Grant Summary
Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy is a NCI - National Cancer Institute grant providing up to $649K for university, nonprofit, healthcare org. Applications are due 2031-05-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $649K
2031-05-31
- 1Confirm your organization is eligible for Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy from NCI - National Cancer Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NCI - National Cancer Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NCI - National Cancer Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy: Frequently Asked Questions
Who is eligible for the Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy?
Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy is offered by NCI - National Cancer Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy provide?
Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy provides up to $649K per award from NCI - National Cancer Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy deadline?
Applications for Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy are due 2031-05-31 (open). Because deadlines can change, verify the date with the funder, NCI - National Cancer Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy?
To apply for Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NCI - National Cancer Institute.